1. Home
  2. CINGW vs MHH Comparison

CINGW vs MHH Comparison

Compare CINGW & MHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • MHH
  • Stock Information
  • Founded
  • CINGW N/A
  • MHH 1986
  • Country
  • CINGW United States
  • MHH United States
  • Employees
  • CINGW 13
  • MHH N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • MHH Professional Services
  • Sector
  • CINGW Health Care
  • MHH Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • MHH Nasdaq
  • Market Cap
  • CINGW N/A
  • MHH N/A
  • IPO Year
  • CINGW 2021
  • MHH N/A
  • Fundamental
  • Price
  • CINGW $0.04
  • MHH $7.79
  • Analyst Decision
  • CINGW
  • MHH
  • Analyst Count
  • CINGW 0
  • MHH 0
  • Target Price
  • CINGW N/A
  • MHH N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • MHH 15.6K
  • Earning Date
  • CINGW N/A
  • MHH 05-07-2025
  • Dividend Yield
  • CINGW N/A
  • MHH N/A
  • EPS Growth
  • CINGW N/A
  • MHH N/A
  • EPS
  • CINGW N/A
  • MHH 0.28
  • Revenue
  • CINGW N/A
  • MHH $198,943,000.00
  • Revenue This Year
  • CINGW N/A
  • MHH $2.17
  • Revenue Next Year
  • CINGW N/A
  • MHH $4.43
  • P/E Ratio
  • CINGW N/A
  • MHH $27.30
  • Revenue Growth
  • CINGW N/A
  • MHH N/A
  • 52 Week Low
  • CINGW N/A
  • MHH $7.15
  • 52 Week High
  • CINGW N/A
  • MHH $16.00
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • MHH 37.27
  • Support Level
  • CINGW N/A
  • MHH $7.26
  • Resistance Level
  • CINGW N/A
  • MHH $8.45
  • Average True Range (ATR)
  • CINGW 0.00
  • MHH 0.78
  • MACD
  • CINGW 0.00
  • MHH -0.01
  • Stochastic Oscillator
  • CINGW 0.00
  • MHH 19.91

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: